What is the fair value of Renalytix AI (OTC-RNLX.Y) stock?

The current fair value estimate for Renalytix AI (OTC-RNLX.Y) is $2.63. This implies an estimated upside of 31.6% versus the current market price.

Is Renalytix AI (OTC-RNLX.Y) undervalued or overvalued?

Based on the current fair value estimate, the stock appears undervalued, with estimated upside of 31.6% versus the current market price.

What is the analyst price target for OTC-RNLX.Y stock?

An analyst price target for Renalytix AI (OTC-RNLX.Y) is not currently available in the latest data file.

How is the financial health of Renalytix AI?

The current financial health read for Renalytix AI (OTC-RNLX.Y) is Fair. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

When is Renalytix AI's next earnings date?

The next earnings date currently listed for Renalytix AI (OTC-RNLX.Y) is September 28, 2026.

Does Renalytix AI (OTC-RNLX.Y) pay dividends?

Based on the current data, dividend yield is 0.0%.

What is the P/E ratio for Renalytix AI (OTC-RNLX.Y)?

The current P/E ratio listed for Renalytix AI (OTC-RNLX.Y) is -0.8x. Use it together with growth, margins and sector comparisons rather than as a standalone valuation signal.

What is the market capitalization of Renalytix AI?

The current market capitalization listed for Renalytix AI is 16.125 M.

What is the enterprise value of Renalytix AI?

The current enterprise value listed for Renalytix AI is 15.747 M. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

What is the ticker symbol for Renalytix AI?

The ticker symbol for Renalytix AI is OTC-RNLX.Y, and the stock is listed on OTC Markets.

Where is Renalytix AI (OTC-RNLX.Y) listed?

Renalytix AI (OTC-RNLX.Y) is listed on OTC Markets.

What is the debt-to-total-capital ratio for Renalytix AI?

The current debt-to-total-capital ratio listed for Renalytix AI is 26.4%, which helps investors evaluate the company’s financing structure and leverage profile.

What is the free float for Renalytix AI?

The free float listed for Renalytix AI is 83.3%. Free float helps investors understand how much of the share base is available for public trading.

Renalytix AI (RNLXY) Fair Value & Stock Analysis

Renalytix AI (RNLXY)

Renalytix AI (RNLXY) is an American depositary receipt representing Renalytix Plc, a London-based healthcare technology company focused on artificial intelligence-enabled diagnostic tools for kidney disease. Its KidneyIntelX platform combines algorithmic analysis with blood-based biomarkers, inherited genetics, and patient data from electronic health records to generate a patient risk score that supports diagnosis, prognosis, clinical care, patient stratification for drug trials, and drug target discovery. The company also has a license agreement with Mount Sinai Health System related to the development and commercialization of its kidney disease diagnostics. Incorporated in 2018, Renalytix Plc was formerly known as Renalytix AI plc and adopted its current name in June 2021.

Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Technical Outlook FAQ

Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.

Ticker	Fair Value	Fair Value Upside/Downside	Fair Value Rating	Analyst Price Target	Analyst Target Upside/Downside	Analyst Target Rating	Overall Financial Health	Upcoming Dividend Ex-Date	Dividend Payment Date	Upcoming Dividend	Dividend Yield	Next Earnings Date	P/E Ratio	Price-to-Book Ratio	Price-to-Sales Ratio	Market Cap	Enterprise Value	Total Debt / Total Capital	Free Float / Shares Outstanding	Altman Z-Score	Payout Ratio	Free Cash Flow / Net Income
OTC-RNLX.Y	$2.63	31.6% Upside	Undervalued	—	—	—	Fair	—	—	—	0.0%	September 28, 2026	-0.8x	-13.5x	4.9x	16.125 M	15.747 M	26.4%	83.3%	-63.2	—	65.8%